The Sarcoma Letter | Brian Schulte | Substack

Olaparib and Temozolomide

Later Line Treatment of Uterine LMS

Aug 14 •

Trends in FDA Approvals for Sarcoma

Where are we going?

Jul 8 •

Second Opinions

Getting the best information

Jun 18 •

Most Popular

Regorafenib for Gastrointestinal Stromal Tumors

Apr 26 • Brian Schulte

The Appointment

May 10 • Brian Schulte

Avapritinib for PDGFRA D842V-Mutant GIST

May 5 • Brian Schulte

Trends in FDA Approvals for Sarcoma

Jul 8 • Brian Schulte

May 29 • Brian Schulte

New

Top

Community

The Cisplatin Shortage

How does it affect treatment?

Jun 12 •

How I discuss treatment of desmoid tumors

A patient-centered approach

Jun 9 •

Reflections on ASCO 2023

The need for more Randomized Controlled Trials

Jun 6 •

A few ASCO Abstracts

A small selection (there will be more)

Jun 1 •

History and Discovery

May 29 •

Imatinib Side Effects

Diagnosis and Management of Common Symptoms

May 27 •

Chemoimmunotherapy for Sarcoma

Doxorubicin and Pembrolizumab

May 23 •

The Sarcoma Letter

The Sarcoma Letter

Everything sarcoma: treatment, multidisciplinary care, the patient journey/experience, and the role of the oncologist

The Sarcoma Letter

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts